Who are abciximab intravenously's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Glycoprotein IIb/IIIa inhibitors, Abciximab + UFH, Bivalirudin with and without eptifibatide, Tirofiban+Oral Dual Antiplatelet Therapy, Eptifibatide Injection, Eptifibatide facilitated PCI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abciximab-intravenously.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

abciximab intravenously — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

abciximab intravenously (abciximab intravenously) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GP IIb/IIIa inhibitor. Area: Cardiovascular.

phase 3 GP IIb/IIIa inhibitor Glycoprotein IIb/IIIa receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

abciximab intravenously (abciximab intravenously) — University of Leipzig. Abciximab inhibits platelet aggregation by binding to the glycoprotein IIb/IIIa receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
abciximab intravenously TARGET	abciximab intravenously	University of Leipzig	phase 3	GP IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor
Glycoprotein IIb/IIIa inhibitors	Glycoprotein IIb/IIIa inhibitors	University of Luebeck	marketed	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor
Abciximab + UFH	Abciximab + UFH	Deutsches Herzzentrum Muenchen	marketed	Glycoprotein IIb/IIIa inhibitor (in combination with anticoagulant)	Platelet glycoprotein IIb/IIIa receptor
Bivalirudin with and without eptifibatide	Bivalirudin with and without eptifibatide	LifeBridge Health	marketed	Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide)	Thrombin (Factor IIa) and Glycoprotein IIb/IIIa receptor
Tirofiban+Oral Dual Antiplatelet Therapy	Tirofiban+Oral Dual Antiplatelet Therapy	Second Affiliated Hospital of Soochow University	marketed	Glycoprotein IIb/IIIa inhibitor + Dual antiplatelet therapy	Glycoprotein IIb/IIIa receptor
Eptifibatide Injection	Eptifibatide Injection	Ministry of Science and Technology of the People´s Republic of China	phase 3	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor
Eptifibatide facilitated PCI	Eptifibatide facilitated PCI	Ottawa Heart Institute Research Corporation	phase 3	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GP IIb/IIIa inhibitor class)

University of Leipzig · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). abciximab intravenously — Competitive Intelligence Brief. https://druglandscape.com/ci/abciximab-intravenously. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing